The low density lipoprotein receptor modulates the effects of hypogonadism on diet-induced obesity and related metabolic perturbations

Journal of Lipid Research

Volumn 55, Issue 7, 2014, Pages 1434-1447

  Constantinou, Caterina ^a   Mpatsoulis, Diogenis ^a   Natsos, Anastasios ^a   Petropoulou, Peristera Ioanna ^a   Zvintzou, Evangelia ^a   Traish, Abdulmaged M ^b   Voshol, Peter J ^c   Karagiannides, Iordanes ^a   Kypreos, Kyriakos E ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Apolipoprotein E; Diabetes o plasma glucose homeostasis; Low density lipoprotein receptor related protein 1; Metabolic activation of white adipose tissue; Metabolic rate; Metabolic syndrome; Testosterone; Uncoupling protein 1

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CYTOCHROME C; GLUCOSE; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; TESTOSTERONE; TRIACYLGLYCEROL; UNCOUPLING PROTEIN 1; LRP1 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN; UCP1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOE GENE; ARTICLE; BLOOD LEVEL; CALORIMETRY; CELL FUNCTION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; GENE; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HORMONE ACTION; HYPOGONADISM; LIPID ANALYSIS; LIPID STORAGE; LRP1 GENE; MALE; METABOLIC ACTIVITY ASSAY; METABOLIC DISORDER; METABOLIC RATE; MITOCHONDRION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; THERMOGENESIS; ANIMAL; CHEMICALLY INDUCED; FAT INTAKE; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHARMACOLOGY;

ANIMALS; APOLIPOPROTEINS E; DIETARY FATS; HYPOGONADISM; MALE; MICE; MICE, KNOCKOUT; OBESITY; RECEPTORS, LDL; TESTOSTERONE; TUMOR SUPPRESSOR PROTEINS; UNCOUPLING PROTEIN 1;

EID: 84903993439     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M050047     Document Type: Article

References (53)

1. Shahidi, N. T. 2001. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin. Ther. 23: 1355-1390.
2. Yassin, A. A., and F. Saad. 2008. Testosterone and erectile dysfunction. J. Androl. 29: 593-604.
3. Traish, A. M., R. Abdou, and K. E. Kypreos. 2009. Androgen defi ciency and atherosclerosis: the lipid link. Vascul. Pharmacol. 51: 303-313.
4. Traish, A. M., F. Saad, and A. Guay. 2009. The dark side of testosterone defi ciency: II. Type 2 diabetes and insulin resistance. J. Androl. 30: 23-32.
5. Traish, A. M., F. Saad, R. J. Feeley, and A. Guay. 2009. The dark side of testosterone defi ciency: III. Cardiovascular disease. J. Androl. 30: 477-494.
6. Traish, A. M., A. Guay, R. Feeley, and F. Saad. 2009. The dark side of testosterone defi ciency: I. Metabolic syndrome and erectile dysfunction. J. Androl. 30: 10-22.
7. Kalyani, R. R., and A. S. Dobs. 2007. Androgen defi ciency, diabetes, and the metabolic syndrome in men. Curr. Opin. Endocrinol. Diabetes Obes. 14: 226-234.
8. Kapoor, D., and T. H. Jones. 2008. Androgen defi ciency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? Drugs Aging. 25: 357-369.
9. Derby, C. A., S. Zilber, D. Brambilla, K. H. Morales, and J. B. McKinlay. 2006. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin. Endocrinol. (Oxf. ). 65: 125-131.
10. Saylor, P. J., and M. R. Smith. 2009. Prostate cancer: how can we improve the health of men who receive ADT? Nat. Rev. Urol. 6: 529-531.
11. Smith, M. R., H. Lee, and D. M. Nathan. 2006. Insulin sensitivity during combined androgen blockade for prostate cancer. J. Clin. Endocrinol. Metab. 91: 1305-1308.
12. Smith, M. R., J. S. Finkelstein, F. J. McGovern, A. L. Zietman, M. A. Fallon, D. A. Schoenfeld, and P. W. Kantoff. 2002. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab. 87: 599-603.
13. Braga-Basaria, M., A. S. Dobs, D. C. Muller, M. A. Carducci, M. John, J. Egan, and S. Basaria. 2006. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J. Clin. Oncol. 24: 3979-3983.
14. Saad, F., L. J. Gooren, A. Haider, and A. Yassin. 2008. A doseresponse study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J. Androl. 29: 102-105.
15. Levine, G. N., A. V. D'Amico, P. Berger, P. E. Clark, R. H. Eckel, N. L. Keating, R. V. Milani, A. I. Sagalowsky, M. R. Smith, and N. Zakai. 2010. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 121: 833-840.
16. Svartberg, J., D. von M̈hlen, E. Mathiesen, O. Joakimsen, K. H. Bønaa, and E. Stensland-Bugge. 2006. Low testosterone levels are associated with carotid atherosclerosis in men. J. Intern. Med. 259: 576-582.
17. Aversa, A., R. Bruzziches, D. Francomano, G. Rosano, A. M. Isidori, A. Lenzi, and G. Spera. 2010. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J. Sex. Med. 7: 3495-3503.
18. Barsh, G. S., I. S. Farooqi, and S. O'Rahilly. 2000. Genetics of bodyweight regulation. Nature. 404: 644-651.
19. Kopelman, P. G. 2000. Obesity as a medical problem. Nature. 404: 635-643.
20. Friedman, J. M. 2000. Obesity in the new millennium. Nature. 404: 632-634.
21. Karagiannides, I., R. Abdou, A. Tzortzopoulou, P. J. Voshol, and K. E. Kypreos. 2008. Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice. FEBS J. 275: 4796-4809.
22. Kypreos, K. E., I. Karagiannides, E. H. Fotiadou, E. A. Karavia, M. S. Brinkmeier, S. M. Giakoumi, and E. M. Tsompanidi. 2009. Mechanisms of obesity and related pathologies: role of apolipoprotein E in the development of obesity. FEBS J. 276: 5720-5728.
23. Hofmann, S. M., L. Zhou, D. Perez-Tilve, T. Greer, E. Grant, L. Wancata, A. Thomas, P. T. Pfl uger, J. E. Basford, D. Gilham, et al. 2007. Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice. J. Clin. Invest. 117: 3271-3282.
24. Karavia, E. A., D. J. Papachristou, I. Kotsikogianni, I. Giopanou, and K. E. Kypreos. 2011. Defi ciency in apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice. FEBS J. 278: 3119-3129.
25. Traish, A. M., K. Park, V. Dhir, N. N. Kim, R. B. Moreland, and I. Goldstein. 1999. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology. 140: 1861-1868.
26. Goss, P. E., S. Qi, A. M. Cheung, H. Hu, M. Mendes, and K. P. Pritzker. 2004. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin. Cancer Res. 10: 5717-5723.
27. Tschöp, M. H., J. R. Speakman, J. R. Arch, J. Auwerx, J. C. Br̈ning, L. Chan, R. H. Eckel, R. V. Farese, Jr., J. E. Galgani, C. Hambly, et al. 2012. A guide to analysis of mouse energy metabolism. Nat. Methods. 9: 57-63.
28. Kypreos, K. E. 2008. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia. Biochemistry. 47: 10491-10502.
29. Duivenvoorden, I., B. Teusink, P. C. Rensen, J. A. Romijn, L. M. Havekes, and P. J. Voshol. 2005. Apolipoprotein C3 defi ciency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes. 54: 664-671.
30. Commins, S. P., P. M. Watson, M. A. Padgett, A. Dudley, G. Argyropoulos, and T. W. Gettys. 1999. Induction of uncoupling protein expression in brown and white adipose tissue by leptin. Endocrinology. 140: 292-300.
31. Ruiz, J., D. Kouiavskaia, M. Migliorini, S. Robinson, E. L. Saenko, N. Gorlatova, D. Li, D. Lawrence, B. T. Hyman, K. H. Weisgraber, et al. 2005. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J. Lipid Res. 46: 1721-1731.
32. Hofmann, S. M., D. Perez-Tilve, T. M. Greer, B. A. Coburn, E. Grant, J. E. Basford, M. H. Tschöp, and D. Y. Hui. 2008. Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-defi cient mice. Diabetes. 57: 5-12.
33. Schaefer, E. J., R. E. Gregg, G. Ghiselli, T. M. Forte, J. M. Ordovas, L. A. Zech, and H. B. Brewer, Jr. 1986. Familial apolipoprotein E defi ciency. J. Clin. Invest. 78: 1206-1219.
34. Puigserver, P., and B. M. Spiegelman. 2003. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev. 24: 78-90.
35. Simpson, E., G. Rubin, C. Clyne, K. Robertson, L. O'Donnell, S. Davis, and M. Jones. 1999. Local estrogen biosynthesis in males and females. Endocr. Relat. Cancer. 6: 131-137.
36. Ḧttemann, M., I. Lee, L. I. Grossman, J. W. Doan, and T. H. Sanderson. 2012. Phosphorylation of mammalian cytochrome c andcytochrome c oxidase in the regulation of cell destiny: respiration, apoptosis, and human disease. Adv. Exp. Med. Biol. 748: 237-264.
37. Nicholls, D. G., and R. M. Locke. 1984. Thermogenic mechanisms in brown fat. Physiol. Rev. 64: 1-64.
38. Kelly, D. M., and T. H. Jones. 2013. Testosterone: a metabolic hormone in health and disease. J. Endocrinol. 217: R25-R45.
39. Brown, M. S., and J. L. Goldstein. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science. 232: 34-47.
40. Kypreos, K. E., B. Teusink, K. W. Van Dijk, L. M. Havekes, and V. I. Zannis. 2001. Analysis of the structure and function relationship of the human apolipoprotein E in vivo, using adenovirus-mediated gene transfer. FASEB J. 15: 1598-1600.
41. Yamamoto, T., H. W. Choi, and R. O. Ryan. 2008. Apolipoprotein E isoform-specifi c binding to the low-density lipoprotein receptor. Anal. Biochem. 372: 222-226.
42. Kypreos, K. E., and V. I. Zannis. 2006. LDL receptor defi ciency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice. J. Lipid Res. 47: 521-529.
43. V́niant, M. M., C. H. Zlot, R. L. Walzem, V. Pierotti, R. Driscoll, D. Dichek, J. Herz, and S. G. Young. 1998. Lipoprotein clearance mechanisms in LDL receptor-defi cient "Apo-B48-only"and "Apo-B100-only" mice. J. Clin. Invest. 102: 1559-1568.
44. Zannis, V. I., A. Chroni, K. E. Kypreos, H. Y. Kan, T. B. Cesar, E. E. Zanni, and D. Kardassis. 2004. Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. Curr. Opin. Lipidol. 15: 151-166.
45. Zannis, V. I., K. E. Kypreos, A. Chroni, D. Kardassis, and E. E. Zanni. 2004. Lipoproteins and atherogenesis. In Molecular Mechanisms of Atherosclerosis. J. Loscalzo, editor. Taylor & Francis, New York. 111-174.
46. Li, X., K. Kypreos, E. E. Zanni, and V. Zannis. 2003. Domains of apoE required for binding to apoE receptor 2 and to phospholipids: Implications for the functions of apoE in the brain. Biochemistry. 42: 10406-10417.
47. Kypreos, K. E., X. Li, K. W. Van Dijk, L. M. Havekes, and V. I. Zannis. 2003. Molecular mechanisms of type III hyperlipoproteinemia: the contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype. Biochemistry. 42: 9841-9853.
48. Kypreos, K. E., P. Morani, K. W. Van Dijk, L. M. Havekes, and V. I. Zannis. 2001. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-defi cient mice. Biochemistry. 40: 6027-6035.
49. Avogaro, P., G. Ghiselli, S. Soldan, and B. G. Bittolo. 1992. Relationship of triglycerides and HDL cholesterol in hypertriglyceridemia. Atherosclerosis. 92: 79-86.
50. Hatch, N. W., S. J. Srodulski, H. W. Chan, X. Zhang, L. R. Tannock, and V. L. King. 2012. Endogenous androgen defi ciency enhances diet-induced hypercholesterolemia and atherosclerosis in low-density lipoprotein receptor-defi cient mice. Gend. Med. 9: 319-328.
51. Gordon, D. J., J. L. Probstfi eld, R. J. Garrison, J. D. Neaton, W. P. Castelli, J. D. Knoke, D. R. Jacobs, Jr., S. Bangdiwala, and H. A. Tyroler. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79: 8-15.
52. Casquero, A. C., J. A. Berti, A. G. Salerno, E. J. Bighetti, P. M. Cazita, D. F. Ketelhuth, M. Gidlund, and H. C. Oliveira. 2006. Atherosclerosis is enhanced by testosterone defi ciency and attenuated by CETP expression in transgenic mice. J. Lipid Res. 47: 1526-1534.
53. Sugiyama, T., Y. Tsugawa, C. H. Tseng, Y. Kobayashi, and M. F. Shapiro. 2014. Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? JAMA Intern. Med. Epub ahead of print. April 24, 2014; doi:10. 1001/jamainternmed. 2014. 1927.